Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
A phase 1/2 trial of MCLA-129 and Ensartinib in advanced solid tumours, run by Betta Pharmaceuticals Co., Ltd., now recruiting.
Overview
Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07448116 by Betta Pharmaceuticals Co., Ltd., with 164 participants planned, started 2026-01-31 and due to reach its primary completion in 2029-02-01. Interventions recorded: MCLA-129 and Ensartinib.
Similar pages
not linked directly; found by shared links- TrialA Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Shares MCLA-129 and the tag pipeline.
- TrialSequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Shares Betta Pharmaceuticals and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.